|
KMID : 0931320100100010001
|
|
대한상부위장관.헬리코박터학회지
2010 Volume.10 No. 1 p.1 ~ p.5
|
|
|
Current Status of Second-line and Third-line Therapy for Helicobacter pylori Eradication in Korea
|
|
Ahn Ji-Yong
Jung Hwoon-Yong
|
|
|
Abstract
|
|
|
|
Eradication of Helicobacter pylori (H. pylori) is needed in many cases. Seven or fourteen day triple therapy (proton pump inhibitor, amoxicillin, and clarithromycin) has been the main first-line therapy in Korea. However, the efficacy of this first-line therapy has become lower and the increase in antimicrobial resistance has happened, recently. When the first-line therapy is failed, seven or fourteen day quadruple regimen (proton pump inhibitor, bismuth salt, metronidazole, and tetracycline) is recommended as the standard second-line therapy in Korea. The eradication rate is 70.4∼96.3% in Korean patients, but the compliance is low. When the first and second-line therapy is failed, there is no standard treatment for H. pylori infection. In the situation of empirical third-line therapies, we can recommend some therapies including levofloxacin, moxifloxacin, and rifabutin. Triple regimen including levofloxacin showed 53.3∼74% eradication rate in Korea. This rate is relatively low, however, the compliance is higher than quadruple second-line regimen. Moxifloxacin-based therapy and rifabutin-based triple therapy have not been studied enough in Korea. Because of these insufficient data, it is difficult to choose proper treatment regimen when second-line therapy is failed. So, we need more well designed randomized controlled studies about third-line therapy. (The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2010;10:1-5)
|
|
|
KEYWORD
|
|
|
Helicobacter pylori, Second-line therapy, Third-line therapy, Eradication rate
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|